Literature DB >> 6288687

Specific molecular activities of recombinant and hybrid leukocyte interferons.

E Rehberg, B Kelder, E G Hoal, S Pestka.   

Abstract

Hybrid interferon DNA recombinants were constructed from the IFLrA and IFLrD leukocyte interferon-coding sequences. Each of the hybrid interferons was purified with the use of a monoclonal antibody to human leukocyte interferon. Three amino acid residues were identified, one or all of which function to potentiate antiviral activity on feline cells and reduce activity on human cells. Because at sufficiently high concentrations human interferons can interact with mouse and rat receptors, it is apparent that the species barrier is only relative and that interferons can be forced into heterologous receptors by mass action. In addition, the specific molecular antiviral and antiproliferative activities (molecules of interferon/cell required for a specific effect) for each of these interferons were determined. The specific molecular activities permit an accurate comparison of the efficacy of different interferons for a specific effect. Because the ratios of antiproliferative/antiviral activity of these interferons vary over a 12-fold range, it appears that the antiviral and antiproliferative activities are promulgated through different mechanisms. To account for these results, it is proposed that there are at least two distinct interferon receptors on cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6288687

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  Structural analysis of the human interferon gamma receptor: a small segment of the intracellular domain is specifically required for class I major histocompatibility complex antigen induction and antiviral activity.

Authors:  J R Cook; V Jung; B Schwartz; P Wang; S Pestka
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

2.  Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display.

Authors:  Jeffrey S Swers; Brenda A Kellogg; K Dane Wittrup
Journal:  Nucleic Acids Res       Date:  2004-02-20       Impact factor: 16.971

Review 3.  The cellular receptor of the alpha-beta interferons.

Authors:  K E Mogensen; G Uzé; P Eid
Journal:  Experientia       Date:  1989-06-15

4.  Interferon-induced alterations in the pattern of parainfluenza virus 5 transcription and protein synthesis and the induction of virus inclusion bodies.

Authors:  T S Carlos; R Fearns; R E Randall
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Peptides and proteins as drugs.

Authors:  B L Ferraiolo; L Z Benet
Journal:  Pharm Res       Date:  1985-07       Impact factor: 4.200

6.  Molecular cloning of a cDNA coding for mouse liver xanthine dehydrogenase. Regulation of its transcript by interferons in vivo.

Authors:  M Terao; G Cazzaniga; P Ghezzi; M Bianchi; F Falciani; P Perani; E Garattini
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

7.  Interferon-induced inhibition of Chlamydia trachomatis: dissociation from antiviral and antiproliferative effects.

Authors:  L M de la Maza; E M Peterson; J M Goebel; C W Fennie; C W Czarniecki
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

8.  Pleiotropic activities of human interferons are mediated by multiple response pathways.

Authors:  R L Forti; W M Mitchell; W C Hubbard; R J Workman; J T Forbes
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

9.  Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferons.

Authors:  J A Leon; M C Gutierrez; H Jiang; A Estabrook; S Waxman; P B Fisher
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Mapuera virus, a rubulavirus that inhibits interferon signalling in a wide variety of mammalian cells without degrading STATs.

Authors:  K Hagmaier; N Stock; B Precious; K Childs; L-F Wang; S Goodbourn; R E Randall
Journal:  J Gen Virol       Date:  2007-03       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.